Back to Authors

Sborov, Douglas W.

https://orcid.org/0000-0003-4268-2698

A5053731124 | I2801159745

Mayo Clinic

Huntsman Cancer Institute

Citations 63

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Blood Advances | February 21, 2021 | Volume: 5 | Issue: 4 | Pages: 1097-1101

10.1182/bloodadvances.2020004017 | PMID 33606005

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1685-1717

10.6004/jnccn.2020.0057 | PMID 33285522

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1154-1165

10.6004/jnccn.2019.0049 | PMID 31590151

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.